MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety
MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.
The test protocol is the document that describes the project and addresses regulatory compliance issues.
Information such as the detailed scope of the project, sample description, test methods and specifications or alert limits are fundamental components to the test protocol.